AmberGen is a privately held Boston-area biotechnology company with over three decades of scientific innovation, dedicated to advancing discovery in spatial biology, diagnostics, and therapeutics. Founded in 1993 to commercialize pioneering photonic technologies developed at Boston University, AmberGen has built a strong foundation in proteomics, mass spectrometry, and light-based control of biomolecules.

The company is widely recognized for its patented photocleavable biotin and mass-tag technologies, which have enabled breakthroughs in protein and oligonucleotide analysis, drug screening, and viral vector control. More recently, AmberGen introduced Miralys™ MALDI-IHC, a highly multiplexed spatial biology imaging platform that has been rapidly adopted by the global mass spectrometry imaging community for high-plex, multiomic tissue analysis. Backed by a minority investment from Bruker Corporation, AmberGen continues to expand its Miralys portfolio with innovative antibody panels and conjugation kits, reinforcing its mission to remove technical barriers and accelerate progress in life sciences research.